TP53, a well-known tumour suppressor gene that encodes p53, is frequently inactivated by mutation or deletion in most human tumours 1, 2 . A tremendous effort has been made to restore p53 activity in cancer therapies [3] [4] [5] [6] [7] . However, no effective p53-based therapy has been successfully translated into clinical cancer treatment owing to the complexity of p53 signalling. Here we demonstrate that genomic deletion of TP53 frequently encompasses essential neighbouring genes, rendering cancer cells with hemizygous TP53 deletion vulnerable to further suppression of such genes. POLR2A is identified as such a gene that is almost always co-deleted with TP53 in human cancers. It encodes the largest and catalytic subunit of the RNA polymerase II complex, which is specifically inhibited by a-amanitin 8, 9 . Our analysis of The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) databases reveals that POLR2A expression levels are tightly correlated with its gene copy numbers in human colorectal cancer. Suppression of POLR2A with a-amanitin or small interfering RNAs selectively inhibits the proliferation, survival and tumorigenic potential of colorectal cancer cells with hemizygous TP53 loss in a p53-independent manner. Previous clinical applications of a-amanitin have been limited owing to its liver toxicity 10 . However, we found that a-amanitin-based antibody-drug conjugates are highly effective therapeutic agents with reduced toxicity 11 . Here we show that low doses of a-amanitin-conjugated anti-epithelial cell adhesion molecule (EpCAM) antibody lead to complete tumour regression in mouse models of human colorectal cancer with hemizygous deletion of POLR2A. We anticipate that inhibiting POLR2A will be a new therapeutic approach for human cancers containing such common genomic alterations.
Genomic deletion of a tumour suppressor gene often encompasses several neighbouring genes that may not contribute to cancer development, but are essential for cell proliferation and survival 12 . This partial loss of essential genes has been postulated to render cancer cells highly vulnerable to further inhibition of those genes 13, 14 . Analysis of TCGA revealed that hemizygous deletion of the TP53 gene occurs frequently in human cancers (Fig. 1a ). We identified POLR2A as an essential gene in the proximity of TP53 (Fig. 1b ). Concomitant deletion of POLR2A occurs in virtually all the human colorectal tumours containing hemizygous TP53 deletion (Fig. 1c) .
Among the 12 subunits in the human RNA polymerase II complex, POLR2A encodes the largest subunit that is indispensable for the polymerase activity in messenger RNA synthesis. Inhibiting POLR2A with a specific inhibitor, a-amanitin, causes extensive cell death, and homozygous deletion of POLR2A is lethal in human cells 9, 15 . We found that 104 (53%) out of 195 colorectal cancer (CRC) cases bear hemizygous loss of the 17p13 region, resulting in concomitant deletion of TP53 and POLR2A (Fig. 1c ). However, no homozygous deletion of POLR2A was observed, consistent with the notion that POLR2A is essential for cell survival. Analysis of TCGA and CCLE databases revealed that expression of POLR2A is tightly correlated with its gene copy number (Fig. 1d ). This positive correlation was also validated in 20 pairs of matched normal and CRC tissue samples and human CRC tissue microarray ( Fig. 1e and Extended Data Fig. 1 ). POLR2A loss (hemizygous loss) cell lines expressed POLR2A proteins at significantly lower levels than POLR2A neutral cell lines ( Fig. 1f-h ). Unlike POLR2A, p53 levels are determined by post-transcriptional and post-translational events 16 . Despite a correlation between TP53 copy number and mRNA expression, p53 protein levels are not associated with its gene copy numbers in human CRC (Extended Data Fig. 2 and Fig. 1h ).
To assess the sensitivity of cells to POLR2A inhibition, a panel of POLR2A neutral (HCT116, SW480) and POLR2A loss (SW837, SNU283) cells were treated with a-amanitin. Treatment of a-amanitin at high concentrations ($1 mg ml 21 ) caused complete cell death in all four cell lines. However, at concentrations ranging from 0 to 1.0 mg ml 21 , a-amanitin inhibition had significantly higher levels of cell-killing effect on the POLR2A loss cells than on the POLR2A neutral cells ( Fig. 2a, b) . The half-maximum inhibitory concentration (IC 50 ) was ,1.0 mg ml 21 for the POLR2A neutral cells, which was tenfold greater than that of the POLR2A loss cells. By contrast, the POLR2A loss cells did not show any greater sensitivity to the treatment of actinomycin D, a nonspecific transcription inhibitor (Extended Data Fig. 3a ). In direct competition assays, the POLR2A neutral cells (HCT116, SW480) stably expressing POLR2A short hairpin RNAs (shRNAs) only had modestly reduced proliferation, in comparison with that of the corresponding cells expressing control shRNAs (Extended Data Fig. 3b , c). However, silencing POLR2A in the POLR2A loss cells (SNU283, SW837) led to markedly reduced proliferation. We generated HCT116 and SNU283 cell lines stably expressing doxycycline (Dox)-inducible POLR2A shRNAs (Extended Data Fig. 3d ). Despite significant knockdown of POLR2A, HCT116 cells continued to proliferate, whereas SNU283 cells exhibited severe G1 cell cycle arrest and apoptosis (Fig. 2c, d and Extended Data Fig. 3e-g ). Approximately 50% of the decrease in POLR2A expression (30-100 ng ml 21 of Dox) remarkably reduced the proliferation of SNU283 cells, but only had a modest effect on HCT116 cells ( Fig. 2d ). Results of rescue experiments demonstrated that gradual re-expression of exogenous POLR2A in SNU283 and SW837 cells restored their resistance to a-amanitin up to a level comparable to that of the POLR2A neutral cells ( Fig. 2e , f and Extended Data Fig. 4 ).
To exclude genetic difference across cell lines, we used the CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 system to generate an isogenic HCT116 cell line with hemizygous loss of POLR2A (refs 17, 18) (Extended Data Fig. 5a -c). POLR2A expression was significantly reduced in the POLR2A loss HCT116 cells (Extended Data Fig. 5d ). The POLR2A loss and parental HCT116 cells exhibited similar proliferation rates (Extended Data Fig. 5e ), indicating that one allele of POLR2A is sufficient to maintain cell proliferation. However, hemizygous deletion of POLR2A markedly sensitized HCT116 cells to a-amanitin treatment with an IC 50 value of ,0.1 mg ml 21 , which is eightfold lower than that of parental HCT116 cells ( Fig. 2g, h) . As a control, no substantial difference on their sensitivity to actinomycin D was observed (Extended Data Fig. 5f ). Knockdown of POLR2A resulted in profoundly reduced proliferation in the POLR2A loss cells, but not in the isogenic POLR2A neutral cells (Extended Data Fig. 5g ). In the isogenic pair of HCT116 cell lines expressing Dox-inducible POLR2A shRNAs, a low-dose of Dox (100 ng ml 21 ) was sufficient to remarkably kill the POLR2A loss cells, while high doses of Dox only had minimal effects on the POLR2A neutral cells (Fig. 2i , j and Extended Data Fig. 5h ).
Blockage of RNA polymerase may lead to p53 accumulation and activation 19 . To examine the effects of p53, we recapitulated the concomitant deletion of TP53 and POLR2A in HCT116 and xenografted human primary CRC (xhCRC) cell lines ( Fig. 3a and Extended Data Fig. 6a -c). The xhCRC cell line (TP53 1/1 POLR2A 1/1 ), established from a freshly isolated xenografted human colon tumour, demonstrated enhanced tumorigenicity in vivo 20 . Except for slightly increased cell proliferation, no significant changes in their sensitivity to a-amanitin were observed in either xhCRC or HCT116 cells with hemizygous deletion of TP53. By contrast, hemizygous loss of POLR2A markedly sensitized these cells to a-amanitin treatment regardless of their TP53 status ( Fig. 3b and Extended Data Fig. 6d -g). The mRNA synthesis activity of the RNA polymerase II is essential to any type of cells including therapy-resistant tumour cells. We examined the drug sensitivity of POLR2A neutral and POLR2A loss cells to three major chemotherapy drugs for CRC: 5-fluorouracil (5-FU), oxaliplatin and 7-ethyl-10-hydroxy-camptothecin (SN-38). Inhibition of POLR2A by a-amanitin significantly enhanced the cell-killing effects of all three drugs in the POLR2A loss xhCRC cells, but had no notable effects on the POLR2A neutral cells ( Fig. 3c ), suggesting therapeutic vulnerability of POLR2A loss colorectal tumours. Free a-amanitin is toxic to liver owing to its interaction with OATP1B3, a transporter exclusively expressed on the membrane of hepatocytes 10 . However, when conjugated with specific antibodies, a-amanitin is no longer a substrate for OATP1B3 (refs 10, 11, 21) . This strategy overcomes the toxicity of a-amanitin for clinical applications. We used a-amanitin conjugated to a monoclonal antibody (HEA125) against EpCAM, a cancer antigen overexpressed in adenocarcinomas 11, 22 . The ama-HEA125 conjugate selectively killed the POLR2A loss xhCRC and HCT116 cancer cells in a p53independent manner, and reduced the effective doses of a-amanitin by at least 10,000-fold (IC 50 , 0.01 ng ml 21 ) in vitro ( Fig. 3d and Extended Data Fig. 6h ).
To test the anti-tumour effect of POLR2A inhibition in vivo, HCT116 and SNU283 cells expressing Dox-inducible POLR2A shRNA were injected subcutaneously into non-obese diabetic/severe LETTER RESEARCH combined immunodeficiency (NOD/SCID) mice. After initial tumour establishment, administration of Dox (1.0 mg ml 21 ) in drinking water suppressed POLR2A expression and consequently inhibited the growth of SNU283-derived tumours (Fig. 4a, b and Extended Data Fig. 7a ). However, no substantial differences were observed between control and POLR2A-knockdown HCT116-derived tumours. Histopathological analyses demonstrated that POLR2A-knockdown SNU283 tumours had significantly reduced cell proliferation, but more apoptotic cells, as compared with the corresponding control tumours (Extended Data Fig. 7b, c) . By contrast, no significant changes were observed in the control or POLR2A-knockdown HCT116 tumours. However, hemizygous deletion of POLR2A sensitized HCT116-derived tumours to Dox treatment (Extended Data Fig. 7d, e ). Next, we used an orthotopic tumour model by injecting POLR2A neutral and POLR2A loss HCT116 cells into the caecal wall of NOD/SCID mice. In vivo tumour imaging demonstrated that Dox-induced POLR2A inhibition led to a significant decrease in tumour growth kinetics in the POLR2A loss tumours, but not in the control POLR2A neutral tumours ( Fig. 4c -e and Extended Data Fig. 7f ). To test the efficacy of POLR2A silencing in vivo further, we used a nanoliposomal delivery platform, DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine), for systemic delivery of POLR2A siRNAs 23 (Extended Data Fig. 8a, b ). After four weeks of systemic therapy, compared with control short interfering RNA (siRNA) and DOPC treatment, mice in the 125 mg kg 21 of POLR2A-siRNA-DOPC treatment groups had pronounced growth reduction of POLR2A loss tumours, while POLR2A neutral tumours only had significant growth inhibition even at the dose of 1,000 mg kg 21 (Extended Data Fig. 8c-h) . 
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Next, we investigated the anti-tumour activity of ama-HEA125 in orthotopic tumour models established by isogenic pairs of xhCRC and HCT116 cells (TP53/POLR2A neutral and TP53/POLR2A loss ) ( Fig. 4f -i and Extended Data Fig. 9a-c) . In a dose-escalation experiment, ama-HEA125 was administered to the tumour-bearing mice as dual intraperitoneal injections at the dose of 3, 10, 30 or 90 mg with respect to a-amanitin per kilograms of mouse body weight. In the mice bearing POLR2A loss tumours, control HEA125-treated mice showed continuous tumour growth within 25 days after antibody injection. The treatment of ama-HEA125 showed strong inhibition on tumour growth even at the lowest dose of 3 mg kg 21 . All the POLR2A loss tumours responded to ama-HEA125 treatment, and tumour volume regressed markedly ( Fig. 4f-i ). Complete tumour regression was observed in 10 out of 10 (90 mg kg 21 ), 8 out of 10 (30 mg kg 21 ) and 6 out of 10 (10 mg kg 21 ) mice bearing POLR2A loss HCT116 tumours 25 days after the first administration of ama-HEA125 ( Fig. 4f, g) . By contrast, significant tumour inhibition was observed in the mice bearing POLR2A neutral tumours only at the highest dose of 90 mg kg 21 , but not at the doses of 3-30 mg kg 21 . Similar results were observed in the mice bearing xhCRC-derived tumours (Fig. 4h, i) . Consistent with our previous study 11 , treatment of ama-HEA125 at the tested doses had no notable toxicity in vivo. Analysis of body weights and blood liver enzymes did not reveal any substantial differences between the ama-HEA125-treated group and the control HEA125-treated group (Extended Data Fig. 9d, e ), suggesting negligible systemic toxicity of the ama-HEA125 conjugate. In addition, we also tested the antitumour activity of ama-HEA125 in orthotopic tumours derived from the POLR2A neutral SW480 cells and the POLR2A loss SW837 cells (Extended Data Fig. 10 ). Treatment of ama-HEA125 at the 10 mg kg 21 dose was sufficient to inhibit tumour growth in all the POLR2A loss tumours, while POLR2A neutral (SW480) or POLR2A-restored (SW837 expressing exogenous POLR2A) tumours were only significantly inhibited by ama-HEA125 at the dose of 90 mg kg 21 .
Much effort has been directed towards restoring p53 activity in human cancer cells 3, 4, 7, 24 . Instead of pharmacological intervention of p53 signalling, the principle of collateral vulnerability to POLR2A inhibition provides a novel strategy for cancer therapy. Our preclinical studies with a-amanitin demonstrate therapeutic efficacy of the strategy for treating CRC. Given that hemizygous loss of TP53 is a frequent genomic event in many human cancers, the therapeutic strategy described here may have broad applications. While clinical applications of a-amanitin are limited by its liver toxicity, conjugation of a-amanitin to antibodies against tumour-specific biomarkers minimizes its systemic toxicity and, moreover, increases the efficacy of treatment. The identification of new pharmacological agents that target POLR2A should significantly impact personalized cancer therapies.
METHODS
Cell culture, antibodies and western blot analysis. HCT116, SW480, SW837, HT29, DLD1 and HT29 cell lines were obtained from the American Type Culture Collection and cultured under standard conditions specified by the manufacturer. SNU283 and SNU1197 cell lines were obtained from the Korean Cell Line Bank and cultured in RMPI 1640 medium supplemented with 10% FBS and 2 mmol l 21 L-glutamine. Isolation, culture and maintenance of xhCRC cells were performed as previously described 20 . In brief, patient-derived xenografts were collected under sterile conditions and mechanically dissociated, followed by 30 min of incubation in collagenase II at 37 uC. The specimen was filtered through a sterile 100-mm strainer. Red blood cells were eliminated with a hypo-osmotic red blood cell lysis buffer (eBioscience). Mouse cells in xenografted human CRC specimens were removed by negative selection using a mouse MHC class I molecule H-2K antibody followed by use of a magnetic bead purification kit (Miltenyi). Fibroblasts were removed by negative selection using a MACS magnetic bead separation kit (Miltenyi). The freshly isolated xhCRC cells were maintained on collagen-1coated culture plates (BD Biosciences) and cultured in MEM supplemented with 10% FBS, vitamins (13) , nonessential amino acids (13), penicillin-streptomycin (13) , sodium pyruvate (13) and L-glutamine (13) . All medium supplements were purchased from Sigma.
Anti-POLR2A antibodies were purchased from Santa Cruz (sc-47701) and Abcam (ab140509). Anti-Ki67 antibody (D3B5) and anti-cleaved caspase-3 (Asp175, 5A1E) antibody were obtained from Cell Signalling. Anti-p53 (sc-126), anti-b-actin (sc-1616), horseradish peroxidase (HRP)-anti-goat IgG (sc-2020), HRP-anti-rabbit IgG (sc-2054), and HRP-anti-mouse IgG (sc-2055) antibodies were purchased from Santa Cruz. Cell lysate preparation, SDS-PAGE and western blotting were performed as previously described 25 . RNA isolation and quantitative PCR. Total RNA was isolated using TRIzol reagent (Life Technologies) and then reverse-transcribed using iScript cDNA Synthesis Kit (Bio-Rad). The resulting cDNA was used for qPCR using iTaq Universal SYBR Green Supermix (Bio-Rad) with gene-specific primers and the results were normalized to b-actin control. In reverse transcription PCR (RT-PCR) assays, the primer sequences for TP53 are: 59-GAGGTTGGCTCTGACTGT ACC-39 and 59-TCCGTCCCAGTAGATTACCAC-39, and for POLR2A are: 59-TTGTATCCGTACCCACAGCA-39 and 59-CATGATCAGCTCCCCATTCT-39. shRNA-mediated knockdown of POLR2A. POLR2A-specific shRNA clones were obtained from the MD Anderson shRNA and ORFeome Core Facility (originally from Open Biosystems). Twelve shRNAs targeting POLR2A were screened, of which two shRNAs knocked down protein levels by at least 50% in all four colorectal cancer cell lines tested. Their clone identification numbers and shRNA sequences are V3LHS_645674 (59-TTAGCTTTGTTCTTCCCGA-39) and V3LHS_640293 (59-TGTTGTCCATCTCCTCCCC-39). The hairpin sequences in the GIPZ vector were cloned into the TRIPZ vector (Dharmacon) using a protocol provided by the manufacturer. The TRIPZ vector is a Doxinducible system with a red fluorescent protein reporter. Generation of cells stably expressing Dox-inducible shRNAs. Recombinant lentiviral particles were produced from 293T cells. In brief, 72 mg of shRNAencoding vector DNA, 54 mg of Delta 8.9 vector DNA and 18 mg of VSVG-encoding vector DNA were transfected into 293T cells (plated in the 245-mm 2 dish) using X-tremeGENE (Roche). Supernatant containing virus particles was collected and filtered 72 h after transfection, concentrated by ultracentrifugation at 90,000g, and resuspended in cell growth medium. To generate stable Dox-inducible cells, HCT116 and SNU283 cells were infected with shRNA-expressing viral particles at a multiplicity of infection (MOI) of 1. Viral solutions were added to cell culture medium containing 4 mg ml 21 polybrene. Cells were selected 48 h after infection by 2 mg ml 21 puromycin. Single colonies were cultured and propagated, and colonies bearing a single copy of lentiviral DNA insert were identified and analysed for knockdown efficiency. Direct competition assay using POLR2A shRNA. A single lentiviral copy expressing either shRNA-1 or shRNA-2 was sufficient to suppress POLR2A expression levels in all the four colorectal cell lines tested (Extended Data Fig.  3b ). Cancer cells were infected with control or POLR2A shRNA-expressing lentiviruses (pGIPZ backbone expressing green fluorescent protein (GFP)) at the MOI of 2. Two days after infection, GFP-positive cells were sorted using a BD FACSJazz cell sorter (BD Biosciences) at the MD Anderson Flow Cytometry and Cellular Imaging Core. Next, GFP-positive cells were mixed with non-infected and GFPnegative cells at the ratio of 1:1 and cultured for six passages. The numbers of GFPpositive and total cells at each passage were analysed and quantified by flow cytometry and the percentages of GFP-positive cells were calculated. Generation of sgRNA-expressing vectors and Surveyor assay. Bicistronic expression vector expressing Cas9 and single-guide RNA (sgRNA) was digested with BbsI and treated with alkaline phosphatase, and then the linearized vector was gel-purified for cloning sgRNA-encoding DNA 26 . The pair of oligonucleotide DNA for each sgRNA targeting TP53 or POLR2A was annealed, phosphorylated and ligated to the linearized vector. The sequences of oligonucleotide DNA are listed in Supplementary Table 1 . Surveyor assay was performed to test the genome editing efficacy as previously described 27,28 . In brief, cells were seeded into six-well plates at a density of 2 3 10 5 cells per well. One day after initial seeding, cells were transfected with 2 mg of Cas9/sgRNA-expressing vector DNA and collected 48 h after transfection. Genomic DNA was isolated and a 1-kb DNA fragment containing the sgRNA-targeting site was amplified by high-fidelity PCR and digested by T7 endonuclease I. Genomic DNA isolated from HCT116 cells transfected with control vector DNA was used as control. To allow complementary but mismatched strands to anneal, PCR products were incubated at 95 uC for 5 min, 95 uC to 85uC at the rate of 22 uC s 21 and 85 uC to 25uC at the rate of 20.1 uC s 21 . T7 endonuclease I was added and samples were incubated at 37 uC for 60 min to digest the annealed PCR products at the mismatch sites. T7-endonuclease-I-digested PCR products were analysed by agarose gel electrophoresis. Oligonucleotide sequences used for PCR amplification are listed in Supplementary  Table 1 . The PCR products from positive clones were ligated to pGEM-T Easy Vector (Promega) and further confirmed by DNA sequencing. Cell proliferation and survival assay. Equal numbers of cells were plated in 12well plates in triplicate. Cells were fixed with 10% methanol and stained with 0.1% crystal violet (dissolved in 10% methanol) at indicated times. After staining, wells were washed three times with PBS and destained with acetic acid. The absorbance of the crystal violet solution was measured at 590 nm. For cell survival assay, cells were seeded at a concentration of 1,000 cells per well in 96-well plates and treated with indicated concentrations of a-amanitin or actinomycin D 24 h later. Cell viability was quantified using WST-1 reagent (Roche) according to the manufacturer's instructions. All experiments were performed in triplicate. Apoptosis and cell cycle analysis. The HCT116 and SNU283 cell lines were treated with or without a-amanitin for 2 days or doxycycline for 4 days at indicated concentrations and stained with annexin-V-phycoerythrin (PE) and 7-AAD (Biovision). Apoptosis was analysed by flow cytometry using a Guava EasyCyte Flow Cytometer (Millipore) according to the manufacturer's protocol. Both preapoptotic (annexin-V-positive and 7-AAD-negative) and apoptotic (annexin-Vpositive and 7-AAD-positive) cells were included in the analyses. For cell cycle analysis, cells were fixed in 75% ethanol at 220 uC overnight. The cells were washed with cold PBS, treated with 100 mg of RNase A (Qiagen), and stained with 50 mg of propidium iodide (Roche). Cell cycle profiles were analysed by flow cytometry using the Guava EasyCyte Flow Cytometer (Millipore). Fluorescence in situ hybridization. FISH analysis was performed using fluorescein-labelled POLR2A (red) and control centromere (chromosome 17, green) probes from Empire Genomics. Hybridization and detection were performed according to the manufacturer's protocols. The slides were counterstained with 49,6-diamidino-2-phenylindole (DAPI), and the images were captured using a Nikon E800 microscope equipped with a cooled-charge coupled device (CCD) camera. To determine hemizygous loss of the POLR2A gene, 100 individual nuclei were analysed for each case. The interphase nuclei were captured and processed using the Quantitative Image Processing System (Applied Imaging). Patient samples. Matched normal and colorectal tumour tissue samples from patients were obtained from the MD Anderson Cancer Center (MDACC) through appropriate informed consents after approval by the Institutional Review Board (IRB PA11-0767). To determine the expression levels of POLR2A protein, tissue samples (20-40 mg) were placed in tubes containing ceramic beads and were homogenized using a Precellys 24 homogenizer device (Bertin Technologies). The lysates were spun-down twice (15 min, 16,000g) and the supernatant was collected. Genomic DNA isolation and copy number validation. Total genomic DNA was extracted from human tissue specimens and cell lines using DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer's purification instructions. All the DNA samples were stored at 220 uC. The copy number variations for POLR2A were determined using TaqMan probes (Hs02023849_cn and Hs01252684_cn) and standard TaqMan PCR kit on an Applied Biosystems 7900HT Sequence Detection System. And the reference gene TERT was simultaneously quantified in the same reaction for each DNA sample. Conjugation of a-amanitin to anti-EpCAM antibody (HEA125). Antibodydrug conjugate ama-HEA125 was constructed by coupling of a-amanitin to lysine residues of the HEA125 antibody by a stable linker structure. HEA125 binds to EpCAM-expressing cells with high affinity (K d , 2.2 3 10 29 mol l 21 ) and high specificity. HEA125 was purified by affinity chromatography using a protein A-Sepharose CL-4B column (GE Healthcare). a-amanitin was attached to immunoglobulin molecules by a plasma stable urea linkage intended to release free a-amanitin inside the tumour cell after lysosomal degradation of the antibody moiety. The drug-antibody ratio of the a-amanitin:IgG molecule was 4:1. Biochemical characteristics of ama-HEA125 were evaluated by high performance liquid chromatography (HPLC) using a PlatinBlue HPLC system (Knauer). In
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addition, HEA125 and ama-HEA125 were analysed by reducing SDS-PAGE and Coomassie staining according to common procedures. Verification of drug-loading was done by anti-amanitin immunoblotting analysis of 30 ng HEA125 and ama-HEA125 using standard techniques. Liposomal nanoparticle preparation. siRNAs for in vivo delivery were encapsulated into DOPC. DOPC and siRNA were mixed in the presence of excess tertiary butanol at a ratio of 1:10 (w/w) siRNA:DOPC. Tween 20 was added to the mixture in a ratio of 1:19 Tween 20:siRNA-DOPC. The mixture was vortexed, frozen in an acetone/dry-ice bath, and lyophilized. Before in vivo administration, this preparation was hydrated with PBS at room temperature at a concentration of 150-1,000 mg siRNA per kilogram per injection (each mouse received 200 ml of DOPC-siRNA-PBS solution by the intraperitoneal route). Xenograft tumour studies. Four-to six-week-old female NOD/SCID mice were purchased from Jackson Laboratories and housed under pathogen-free conditions. All studies were approved and supervised by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. When used in a power calculation, our sample size predetermination experiments indicated that five mice per group can identify the expected effect of POLR2A on tumour size and weight (P , 0.05) with 90% power. Animals were randomly divided to different groups. Dox-inducible HCT116 (1 3 10 6 ) and SNU283 (2 3 10 6 ) cells in 50 ml growth medium (mixed with Matrigel at 1:1) were injected subcutaneously into the flank using a 100-ml Hamilton microlitre syringe. Tumour size was measured every 3 days using a calliper, and tumour volume was calculated using the standard formula: 0.5 3 L 3 W 2 , in which L is the longest diameter and W is the shortest diameter. For orthotopic mouse model, the NOD/SCID mice were anaesthetized and the skin was incised to expose caecum. Dox-inducible HCT116 cells (1 3 10 6 ) expressing luciferase were injected into the caecal wall using a 100-ml Hamilton microlitre syringe, and then the incision was closed using wound clips. Tumours were monitored by the IVIS system after luciferin injection for 15 min. After initial establishment of tumour (100 mm 3 for subcutaneous implants and 2 3 10 8 photons per second, total flux for orthotopic implants), mice were treated with 1 mg ml 21 doxycycline in drinking water for 3-4 weeks. The doxycycline water was changed every other day.
For xenograft tumour studies using DOPC-encapsulated siRNAs, isogenic pairs of HCT116 (1 3 10 6 ) cells were transplanted into the caecal wall using a 100-ml Hamilton microlitre syringe. Ten days after cell injection, mice were randomly divided and assigned to receive either control-siRNA-DOPC or POLR2A-siRNA-DOPC. The siRNA sequences are as follows: control siRNA (59-UUCUCCGAAC GUGUCACGU-39 and 59-ACGUGACACGUUCGGAGAA-39); POLR2A siRNA-1 (59-CCAACAUGCUGACAGAUAU-39 and 59-AUAUCUGUCAGCA UGUUGG-39); POLR2A siRNA-2 (59-CCAAGAAGCGGCUCACACA-39 and 59-UGUGUGAGCCGCUUCUUGG-39). A dose of 150-1,000 mg siRNA per kilogram mouse was administrated intraperitoneally at twice weekly intervals. This range of concentrations was determined by the Center for RNA Interference and Noncoding RNAs at MD Anderson Cancer Center, which ensures efficient delivery and knockdown of target genes as previously described 23 .
For xenograft tumour studies using ama-HEA125 antibody-drug conjugate, isogenic pairs of HCT116 (1 3 10 6 ), xhCRC (0.5 3 10 6 ), SW480 (1 3 10 6 ) or SW837 (2 3 10 6 ) cells were transplanted into the caecal wall using a 100-ml Hamilton microlitre syringe. Mice bearing 10-day-old tumours were randomized to five groups (n 5 10 mice per group) and received two intraperitoneal doses (at 10 days and 17 days, 1 week apart) of the following: (1) control unconjugated HEA125 monoclonal antibody at a dose of 3.6 mg kg 21 of body weight; (2) ama-HEA125 at a dose of 90 mg kg 21 in terms of a-amanitin (corresponding to 3.6 mg kg 21 of IgG); (3) ama-HEA125, 30 mg kg 21 in terms of a-amanitin (corresponding to 1.2 mg kg 21 of IgG); (4) ama-HE125, 10 mg kg 21 in terms of a-amanitin (corresponding to 0.4 mg kg 21 of IgG); and (5) ama-HEA125, 3 mg kg 21 in terms of a-amanitin (corresponding to 0.12 mg kg 21 of IgG). Tumours were monitored by the IVIS live imaging system twice a week after luciferin injection for 15 min. Body weights were recorded every four days. Blood was obtained by retro-orbital bleeding after anaesthesia on day 21 and levels of blood liver enzymes (aspartate amino transferase, amino alanine transferase and alkaline phosphatase) were determined at the Clinical Pathology, Veterinary Medicine and Surgery Core of MD Anderson Cancer Center.
The person who provided animal care and measured tumour growth was blinded to the group allocation during all animal experiments and outcome assessment. Mice were euthanized when they met the institutional euthanasia criteria for tumour size and overall health condition. Tumours were removed, photographed and weighed. The freshly dissected tumour tissues were fixed in 10% buffered formalin overnight, washed with PBS, transferred to 70% ethanol, embedded in paraffin, sectioned and stained with haematoxylin and eosin. The investigators were blinded to the group allocation during the experiment and when assessing the outcome. Immunohistochemistry and human colon tissue microarray. Colon cancer tissue microarray (BC051110a) was purchased from Biomax, including 110 colon tumour samples and 10 nomral colon tissue samples. Samples were deparaffinized and rehydrated. Antigen was retrieved using 0.01 M sodium citrate buffer (pH 6.0) at a sub-boiling temperature for 10 min after boiling in a microwave oven. To block endogenous peroxidase activity, the sections were incubated with 3% hydrogen peroxide for 10 min. After 1 h of pre-incubation in 5% normal goat serum to prevent nonspecific staining, the samples were incubated with antibody against POLR2A (sc-47701, Santa Cruz), Ki67, (D3B5, Cell Signaling), or cleaved caspase-3 (5A1E, Cell Signaling) at 4 uC overnight. The sections were incubated with a biotinylated secondary antibody (4Plus Biotinylated anti-mouse or anti-rabbit IgG, BioCARE) and then incubated with avidin-biotin peroxidase complex solution and developed using a DAB (diaminobenzidine) substrate kit (550880, BD Biosciences) according to the manufacturer's protocol. Counterstaining colour was carried out using Harris modified haematoxylin. All immunostained slides were scanned on the Automate Cellular Image System III (ACIS III) for quantification by digital image analysis. Bioinformatic analysis. We analysed the correlation between gene copy number and the corresponding gene expression using data obtained from CCLE (http:// www.broadinstitute.org/ccle) and TCGA (http://www.cbioportal.org/publicportal/) as previously described 13 . Enrichment of Pearson correlation coefficients was determined by permuting gene names. To determine whether a deleted gene functions as a housekeeping gene, we first analysed its expression profiles in tumour and normal tissues as well as its general functions from literature. Second, we checked gene conservation across species and lethality of the gene knockout by searching available databases of model organisms (Saccharomyces Genome Database, WormBase, FlyBase and Mouse Genome Informatics). Third, we checked the proximity of the potential target gene to the TP53 gene and analysed its co-deletion with TP53 in human cancers. Finally, we searched for available cancer cell lines with the deletion of TP53 and the target gene to test our hypothesis. Statistical analysis. Each experiment was repeated three times or more. Unless otherwise noted, data are presented as mean and s.d. or s.e.m., and Student's t-test (unpaired, two-tailed) was used to compare two groups of independent samples. In an unpaired t-test, we assumed equal variance and no samples were excluded from the analysis. Statistical methods used for TCGA data analysis are described above. P , 0.05 was considered statistically significant. 
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